File Name: pharmacokinetic and pharmacodynamic drug interactions writer.zip
Drug metabolism, pharmacokinetics and toxicokinetics as determinants of drug attrition and the safety of xenobiotics are critically important. This book presents a comprehensive treatise on the current issues and challenges facing drug metabolism and pharmacokinetics.
- Pharmacokinetic and Pharmacodynamic Drug Interactions Associated with Antiretroviral Drugs
- Drug Metabolism and Pharmacokinetics
- Current Drug Metabolism
Warfarin: pharmacological profile and drug interactions with antidepressants.
Pharmacokinetic and Pharmacodynamic Drug Interactions Associated with Antiretroviral Drugs
In the current pandemic scenario, publication process of all articles related to Coronavirus will be expedited, for timely publication of much needed research. Current Drug Metabolism aims to cover all the latest and outstanding developments in drug metabolism, pharmacokinetics, and drug disposition.
Current Drug Metabolism is an essential journal for academic, clinical, government and pharmaceutical scientists who wish to be kept informed and up-to-date with the most important developments. The journal covers the following general topic areas: pharmaceutics, pharmacokinetics, toxicology, and most importantly drug metabolism.
More specifically, in vitro and in vivo drug metabolism of phase I and phase II enzymes or metabolic pathways; drug-drug interactions and enzyme kinetics; pharmacokinetics, pharmacokinetic-pharmacodynamic modeling, and toxicokinetics; interspecies differences in metabolism or pharmacokinetics, species scaling and extrapolations; drug transporters; target organ toxicity and interindividual variability in drug exposure-response; extrahepatic metabolism; bioactivation, reactive metabolites, and developments for the identification of drug metabolites.
Preclinical and clinical reviews describing the drug metabolism and pharmacokinetics of marketed drugs or drug classes. Search Advanced Search. Toggle navigation. Impact Factor: 2. Subscribe to this Journal. Book Proposal. Become an Executive Guest Editor. New Journal Proposal.
Become a Section Editor. Become a Reviewer. Join Editorial Board. Thematic Issue Proposal. Submit Abstract Online. View Biography. Singla DOI: View Editorial Permissions. Review Article. Review Article Mini-Review. Abul Barkat DOI: Articles Ahead of Print. Benner and Kenneth L.
Feenstra DOI: Abstracts Ahead of Print. Evaluation of dermorphin metabolism using zebrafish water tank model and human liver microsomes Juliana de L. Martucci DOI: Thombre and Jiaur R. Marufur Rahman Moni, Mst. Marium Begum, Md. Published Contents. Editor's Choice. Alreshidi, Mohd. Open Access Articles. Most Cited Articles. Research Article. General Research Article. Most Accessed Articles. His research interests include bioavailability of drugs, nutrients, and micronutrients with emphasis on mechanisms of absorption and metabolism of flavonoids and phenolic drugs.
Hu has published several articles in well-reputed journals. COPE Compliant. About the Journal. For Authors. For Guest Editors. For Reviewers. Quick Links. Journal History. Current Drug Metabolism was launched in Ming Hu serves as the Editor-in-Chief of the journal.
Scopus CiteScore Metrics: 2. Related Journals. Related eBooks. Webmaster Contact: info benthamscience.
Drug Metabolism and Pharmacokinetics
Identifying drug-drug interactions DDIs is a major challenge in drug development. Previous attempts have established formal approaches for pharmacokinetic PK DDIs, but there is not a feasible solution for pharmacodynamic PD DDIs because the endpoint is often a serious adverse event rather than a measurable change in drug concentration. Our prediction was robust and surpassed existing methods as validated by two independent GSPs. Analysis of clinical side effect data suggested that the drugs having predicted DDIs have similar side effects. We further incorporated this clinical side effects evidence with S-score to increase the prediction specificity and sensitivity through a Bayesian probabilistic model. Importantly, our algorithm provided opportunities for better understanding the potential molecular mechanisms or physiological effects underlying DDIs, as illustrated by the case studies. Drug-drug interaction DDI is an important problem in clinical practice.
In particular, poly-therapy increases the complexity of therapeutic management and thereby the risk of clinically important DDIs, which can both induce the development of adverse drug reactions or reduce the clinical efficacy. DDIs can be classify into two main groups: pharmacokinetic and pharmacodynamic. In this review, using Medline, PubMed, Embase, Cochrane library and Reference lists we searched articles published until June 30 , and we described the mechanism of pharmacokinetic DDIs focusing the interest on their clinical implications. Pharmacovigilance or post-marketing surveillance aims to identify and quantify the risks associated with the use of drugs, thus contributing to better understand the most important characteristics of adverse drug reactions ADRs and the pathogenic mechanisms involved. Drug-drug interactions DDIs are one of the commonest causes of ADRs and we reported that these manifestations are commons in the elderly due to poly-therapy. Pharmacokinetic: Involves absorption, distribution, metabolism and excretion, all of them being associated with both treatment failure or toxicity;. In this review, we described the mechanism of pharmacokinetic DDI focusing the interest on their clinical implications, addressing the reader's attention for pharmaceutical interactions to other original and review articles.
Current Drug Metabolism
Malaria and tuberculosis TB are two major global diseases mostly affecting the developing countries. Their treatment is often complex because of the drugs used, multidrug resistance, drug interactions and logistic problems such as drug availability and access. Patients are treated for TB for a minimum of 6 months and may concomitantly develop and be treated for malaria, especially during the rainy season. Rifampicin, a standard component of combination regimens for treating TB, is a potent inducer of hepatic cytochrome and other metabolic enzymes and is able to influence the pharmacokinetics of many drugs.
Нуматака удовлетворенно мотнул головой. Хорошая новость. Звонок из Соединенных Штатов. Он улыбнулся. Значит, все правда. - Из какого именно места в Штатах? - спросил .
Сьюзан и Соши занялись поисками во Всемирной паутине. - Лаборатория вне закона? - спросила Сьюзан. - Это что за фрукт. Соши пожала плечами.
Сьюзан удалось протиснуть в щель плечо. Теперь ей стало удобнее толкать. Створки давили на плечо с неимоверной силой. Не успел Стратмор ее остановить, как она скользнула в образовавшийся проем. Он попытался что-то сказать, но Сьюзан была полна решимости.